Citi is out with its report today on Bristol-Myers Squibb BMY, maintaining Buy.
In a note to clients, Citi writes, "We rate BMY stock Buy/Medium Risk (1M). BMY offers a strong stable of late-stage pipeline assets (Yervoy, Eliquis, Nnulogix, dapagliflozin, Orencia subcutaneous), which we believe has the Company well-positioned to grow earnings off of its 2013 trough year. The company is also supported by an attractive ~5% dividend yield and has a management team that is focused on increasing shareholder value."
Shares of BMY closed Friday at $29.12, down 0.85% from Thursday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in